Anti-Atezolizumab Antibodies

s

s

s

Antibodies for bioanalysis and drug monitoring of atezolizumab and biosimilars

Develop highly selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for the monoclonal antibody atezolizumab (Tecentriq) using our range of ready-made antibodies.

• Recombinant antibodies specific to atezolizumab
• TrailBlazer Antibodies enabling site-directed conjugation and format switching
• Fully human format for surrogate positive control or calibrator
• Sequence-defined, well characterized reagents with secure supply
• Stringent quality control for batch-to-batch consistency

Table 1. Antibodies Specific to Atezolizumab and Atezolizumab- PD-L1 Complex

* Affinity measured in the monovalent Fab format
¹ Fab-F-Spy2-H = Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags
² Fab2-FH-X22-HRP= Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags and Fab-SpyTag coupled to HRP conjugated BiCatcher

Anti-Atezolizumab Inhibitory Antibodies (Type 1)

Type 1 anti-atezolizumab antibodies inhibit the binding of the monoclonal antibody drug atezolizumab to its target, programmed cell death ligand 1 (PD-L1). They are ideal for development of a PK bridging ELISA to measure free drug. Three clones are available in fully human IgG1 format for use as a surrogate positive control or reference standard in an ADA assay.

Anti-Atezolizumab PD-L1 Complex Specific Antibody (Type 3)

The Type 3 antibodies specifically recognize the drug-target complex, detecting atezolizumab only when it is bound to its target PD-L1. They are suitable as a detection antibody in a PK antigen capture assay.

TrailBlazer Antibodies

TrailBlazer™ Antibodies, clone AbD40638ad (TZA011) and AbD40640ad (TZA013) have a SpyTag2 incorporated at the C-terminus of the antibody heavy chain. In a fast reaction that simply requires mixing at room temperature, these antibodies can form a covalent isopeptide bond to a SpyCatcher reagent, enabling site-directed conjugation or fast conversion to a bivalent Fab or a full-length Ig-like format within an hour.

ELISA Protocols to Get You Started

PK Bridging ELISA 

Fig. 1. Atezolizumab PK bridging ELISA using antibodies TZA011 and HCA381.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.

PK Antigen Capture ELISA

Fig. 2. Atezolizumab PK antigen capture ELISA using antibody TZA0013P.

Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, Fab2 antibody (purple), and BiSpyCatcher2 (gray) labeled with HRP (orange).

ADA Bridging ELISA

Fig. 3. Atezolizumab ADA bridging ELISA using antibody HCA380, HCA381, or HCA382.

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Resources

Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.